Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 68.9 Cr.
- Current Price ₹ 5.28
- High / Low ₹ 15.2 / 5.01
- Stock P/E
- Book Value ₹ 5.16
- Dividend Yield 0.00 %
- ROCE 4.93 %
- ROE 1.52 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 1.00 times its book value
- Debtor days have improved from 221 to 172 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.5% over past five years.
- Promoter holding is low: 31.6%
- Company has a low return on equity of 6.31% over last 3 years.
- Earnings include an other income of Rs.3.57 Cr.
- Company has high debtors of 172 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121 | 95 | 67 | 64 | 68 | 75 | 60 | 54 | 76 | 70 | 86 | 99 | 114 | |
| 118 | 95 | 66 | 60 | 65 | 73 | 59 | 51 | 69 | 60 | 85 | 98 | 116 | |
| Operating Profit | 2 | -0 | 1 | 3 | 3 | 2 | 1 | 3 | 7 | 9 | 2 | 1 | -2 |
| OPM % | 2% | -0% | 1% | 5% | 4% | 3% | 2% | 5% | 9% | 13% | 2% | 1% | -2% |
| 1 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit before tax | 1 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 6 | 9 | 1 | 1 | -0 |
| Tax % | 50% | -7% | 300% | 32% | 41% | 37% | 62% | 26% | 30% | 25% | 23% | 34% | |
| 0 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 4 | 7 | 1 | 1 | -1 | |
| EPS in Rs | 0.38 | 0.20 | -0.04 | 0.15 | 0.08 | 0.07 | 0.00 | 0.10 | 0.38 | 0.63 | 0.07 | 0.08 | -0.09 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 94% |
| 3 Years: | -41% |
| TTM: | -223% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -29% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 3 | 7 | 7 | 11 | 11 | 11 | 11 | 11 | 26 | 26 |
| Reserves | 3 | 3 | 3 | 1 | 14 | 15 | 11 | 12 | 16 | 30 | 32 | 39 | 41 |
| 19 | 25 | 21 | 23 | 18 | 17 | 17 | 18 | 21 | 15 | 13 | 12 | 16 | |
| 32 | 17 | 25 | 18 | 25 | 30 | 28 | 46 | 34 | 24 | 24 | 33 | 39 | |
| Total Liabilities | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
| 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| 53 | 44 | 48 | 43 | 62 | 67 | 64 | 84 | 80 | 76 | 77 | 107 | 114 | |
| Total Assets | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7 | -4 | 5 | 0 | -9 | 4 | 3 | 2 | 1 | 1 | 1 | -18 | |
| -0 | 2 | 3 | 1 | 1 | -0 | -0 | -0 | -1 | 0 | 1 | -0 | |
| 6 | 2 | -8 | -1 | 8 | -4 | -3 | -2 | 0 | -2 | -1 | 18 | |
| Net Cash Flow | -1 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 1 | -0 | 1 | 0 |
| Free Cash Flow | -8 | -5 | 5 | 0 | -10 | 4 | 3 | 2 | 0 | 1 | 1 | -18 |
| CFO/OP | -276% | 1,252% | 842% | 16% | -326% | 212% | 433% | 78% | 31% | 28% | 185% | -3,104% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116 | 133 | 221 | 214 | 240 | 240 | 286 | 453 | 282 | 281 | 209 | 172 |
| Inventory Days | 26 | 13 | 20 | 7 | 11 | 5 | 6 | 5 | 4 | 20 | 2 | 20 |
| Days Payable | 99 | 66 | 145 | 100 | 136 | 130 | 169 | 321 | 163 | 120 | 95 | 116 |
| Cash Conversion Cycle | 43 | 80 | 96 | 121 | 115 | 115 | 123 | 137 | 122 | 181 | 116 | 77 |
| Working Capital Days | 59 | 98 | 25 | 14 | 97 | 98 | 124 | 146 | 111 | 208 | 169 | 231 |
| ROCE % | 19% | 14% | 13% | 16% | 13% | 10% | 7% | 10% | 19% | 22% | 6% | 5% |
Insights
In beta| Mar 2017 | Mar 2019 | Aug 2020 | Feb 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Countries Presence Number |
|
||||
| Number of Approved Product Registrations Number |
|||||
| Number of Customers Number |
|||||
| Number of Employees Number |
|||||
| Number of Registered Brands Number |
|||||
| Number of Brands in Pipeline Number |
|||||
| Number of Manufacturing Sites (Third Party) Number |
|||||
| Pending Order Book INR Crores |
|||||
| Pending Order Book (Formulations/Export) INR Crores |
|||||
| Total Number of Products Number |
|||||
Documents
Announcements
-
Trading Window
28 March 2026 - Trading window closed from 01-Apr-2026 until 48 hours after audited FY2026 results release.
-
Shareholders meeting
16 March 2026 - Postal ballot (notice Feb 13, 2026) approves preferential equity issuance; 25,413,011 votes for, 2,310 against.
-
Shareholders meeting
28 February 2026 - Corrigendum: preferential issue at Rs20/share to acquire 51.02% of Kesar Pharma; floor Rs9.46; voting ends 15 Mar 2026
-
Copy of Newspaper Publication
17 February 2026 - Postal ballot notice advertised in Active Times and Mumbai Lakshdeep on 17 Feb 2026.
-
Copy of Newspaper Publication
17 February 2026 - Board approved and published unaudited Q3 and nine-month results ended 31-Dec-2025; ad on 17 Feb 2026.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations